875573-63-0 Usage
Uses
Used in Pharmaceutical Research and Development:
(7alpha,17beta)-17-(Acetyloxy)-7-(9-bromononyl)estr-4-en-3-one is used as a research compound for investigating its potential therapeutic effects and mechanisms of action in hormonal disorders and reproductive health. Its unique structural modifications may provide insights into the development of novel drugs with improved efficacy and safety profiles.
Used in Hormonal Disorder Treatment:
In the pharmaceutical industry, (7alpha,17beta)-17-(Acetyloxy)-7-(9-bromononyl)estr-4-en-3-one is used as a potential therapeutic agent for treating hormonal imbalances and related disorders. Its modified structure may offer advantages over existing treatments, such as increased selectivity for target receptors or improved pharmacokinetic properties, leading to better patient outcomes.
Used in Reproductive Health Applications:
(7alpha,17beta)-17-(Acetyloxy)-7-(9-bromononyl)estr-4-en-3-one is used as a compound of interest in reproductive health research, where it may contribute to the development of new treatments for fertility issues, menstrual disorders, or pregnancy-related conditions. Its unique properties could potentially address unmet needs in this field and improve reproductive health outcomes for patients.
Check Digit Verification of cas no
The CAS Registry Mumber 875573-63-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,5,5,7 and 3 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 875573-63:
(8*8)+(7*7)+(6*5)+(5*5)+(4*7)+(3*3)+(2*6)+(1*3)=220
220 % 10 = 0
So 875573-63-0 is a valid CAS Registry Number.
875573-63-0Relevant academic research and scientific papers
Impurity control method of fulvestrant
-
, (2020/09/23)
The invention belongs to the field of pharmaceutical chemicals, and relates to a fulvestrant impurity control method, which is characterized in that from the introduction of chiral carbon to the synthesis of a fulvestrant intermediate compound represented by a formula VII-1, multi-step and step-by-step control is performed on 7beta isomer impurities, so that the 7beta isomer content of the VII-1 compound is between 0.1% and 0.3%, and finally the qualified fulvestrant bulk drug with stable quality is prepared. The impurity control method is simple to operate, low in production cost and high intotal yield, and can be applied to large-scale industrial production.
An alternative synthesis of the breast cancer drug fulvestrant (Faslodex): catalyst control over C-C bond formation
Caprioglio, Diego,Fletcher, Stephen P.
supporting information, p. 14866 - 14868 (2015/10/06)
Fulvestrant (Faslodex) was synthesized in four steps (35% overall yield) from 6-dehydronandrolone acetate. Catalyst controlled, room temperature, diastereoselective 1,6-addition of the zirconocene derived from commercially available 9-bromonon-1-ene was used in the key C-C bond forming step.
Process for the preparation of 7alpha-alkylated 19-norsteroids
-
Page/Page column 24, (2008/06/13)
Processes useful in the preparation of pharmaceutical compounds such as fulvestrant and processes for the preparation of fulvestrant.
